Understand the source comparison
DSIP for Shift Work Sleep Disorder Research: Comparison
DSIP GABAergic modulation + SCN regulation Increases slow-wave sleep 20–30% without suppressing REM (animal data) Proposed SCN phase-shifting effects; limited human validation 1–2 small uncontrolled trials; no Phase III data Mechanistically promising but clini
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DSIP
- GABAergic modulation + SCN regulation
- Increases slow-wave sleep 20–30% without suppressing REM (animal data)
- Proposed SCN phase-shifting effects; limited human validation
- 1–2 small uncontrolled trials; no Phase III data
- Mechanistically promising but clinically unproven. Confined to research settings
- Melatonin (0.5–5 mg)
- MT1/MT2 receptor agonism; phase-shifts SCN
- Minimal direct effect on sleep stages; reduces latency modestly
- Well-documented phase advance/delay effects; dose- and timing-dependent
- Multiple RCTs in shift workers; Cochrane review shows modest benefit
- Evidence-based for circadian phase adjustment; weak hypnotic effect
- Modafinil (100–200 mg)
- Dopamine reuptake inhibition; orexin activation
- No direct sleep-promoting effect; wakefulness agent
- No circadian realignment; treats alertness symptoms only
- FDA-approved for shift work sleep disorder; multiple Phase III trials
- Effective for on-shift alertness; does not improve off-shift sleep quality
- Zolpidem (5–10 mg)
- GABA-A α1 subunit selective agonist
- Reduces sleep latency; suppresses slow-wave and REM sleep
- No circadian effect; purely hypnotic
- Extensive data in general insomnia; minimal shift work-specific trials
- Forces sleep onset but worsens architecture; rebound insomnia risk
- The comparison underscores a recurring theme in DSIP for shift work sleep disorder research: theoretical advantages over existing pharmacotherapy do not equate to clinical validation. Melatonin's circadian effects are well-characterised but require precise timing relative to the individual's circadian phase. Most shift workers mistakenly take it immediately before bed, which can worsen misalignment. Modafinil treats the consequence (excessive sleepiness during work) without addressing the cause (circadian desynchrony). DSIP theoretically targets the root mechanism, but the evidence gap between animal studies and real-world application is vast.